---
schema_version: "secwatch.filing_event.v1"
accession: "0001411685-24-000039"
form_type: "8-K"
ticker: "VTGN"
cik: "0001411685"
company_name: "Vistagen Therapeutics, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:39:16.614062+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vistagen Q1 FY2025 net loss $10.7M; PALISADE Phase 3 trials on track for 2025 results

## Summary
- Net loss of $10.7M for Q1 FY2025, up from $6.9M in Q1 FY2024.
- Cash, cash equivalents, and marketable securities at $108.4M as of June 30, 2024.
- PALISADE-3 Phase 3 trial for fasedienol in SAD on track for top-line results in 2025.
- PALISADE-4 Phase 3 trial preparation ongoing; initiation planned H2 2024.
- R&D expenses increased to $7.6M from $4.2M due to PALISADE trial costs.

## SEC filing metadata
- accession: 0001411685-24-000039
- form_type: 8-K
- ticker: VTGN
- cik: 0001411685
- company_name: Vistagen Therapeutics, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000039/0001411685-24-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411685/000141168524000039/vtgn-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001411685-24-000039
- JSON: https://secwatch.observer/filing/0001411685-24-000039.json
- Plain text: https://secwatch.observer/filing/0001411685-24-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.